Clinical Trials
5
Active:0
Completed:5
Trial Phases
2 Phases
Phase 3:4
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 3
4 (80.0%)Phase 4
1 (20.0%)Safety & Efficacy of a Combination Niacin ER/Simvastatin in Patients With Dyslipidemia: A Dose-Ranging Study - SEACOAST
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2004-05-05
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Kos Pharmaceuticals
- Registration Number
- NCT00082251
Evaluation of the Safety & Efficacy of a Combination of Niacin ER & Simvastatin in Patients With Dyslipidemia (OCEANS)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2004-03-29
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Kos Pharmaceuticals
- Target Recruit Count
- 600
- Registration Number
- NCT00080275
Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
Phase 4
Completed
- Conditions
- DyslipidemiaCoronary Heart DiseaseAtherosclerosisStrokeDiabetes
- First Posted Date
- 2004-03-12
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Kos Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00079638
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
Phase 3
Completed
- Conditions
- Intermittent ClaudicationPeripheral Vascular Disease
- First Posted Date
- 2003-10-20
- Last Posted Date
- 2006-11-02
- Lead Sponsor
- Kos Pharmaceuticals
- Target Recruit Count
- 870
- Registration Number
- NCT00071266
- Locations
- 🇺🇸
Tatum Ridge Internal Medicine, Phoenix, Arizona, United States
🇺🇸Scottsdale Cardiovascular Research Institute, LLC, Scottsdale, Arizona, United States
🇺🇸VA Palo Alto Health Care System, Palo Alto, California, United States
Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication
Phase 3
Completed
- Conditions
- Intermittent ClaudicationPeripheral Vascular Disease
- First Posted Date
- 2003-06-12
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Kos Pharmaceuticals
- Target Recruit Count
- 366
- Registration Number
- NCT00062556
News
No news found